Alto Neuroscience, Inc. announced positive results from an independent, prospective replication study evaluating electroencephalography (EEG) biomarkers in people with schizophrenia. The study successfully replicated previous findings, demonstrating that event-related theta-band responses, specifically theta-band inter-trial coherence (ITC), robustly differentiate individuals with schizophrenia from healthy controls.
The analysis, which included 155 individuals with schizophrenia and 272 healthy controls, showed that theta ITC and event-related spectral perturbation (ERSP) had the largest case-control differences, surpassing traditional EEG measures. Importantly, both theta ITC and ERSP were significantly correlated with processing speed, a key domain of cognitive impairment in schizophrenia (CIAS).
These findings provide strong validation for using theta ITC as an objective, brain-based measurement in identifying and evaluating patients with CIAS. Alto is currently utilizing theta ITC as a key biomarker and primary outcome measure in its ongoing Phase 2 study of ALTO-101, an investigational novel PDE4 inhibitor for the treatment of CIAS, enhancing confidence in the trial's relevance and potential for success.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.